Business Standard

Dr Reddy's Lab rises 2.3%

Related News

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.

Read more on:   
|

Quick Links

 

Market News

JSPL shares tank after CBI case against company

Shares of Jindal Steel and Power Ltd (JSPL) tumbled about seven per cent, eroding Rs 1,161.2 crore from its market value, after a case of ...

Restructuring should precede PSU disinvestment

The disinvestment target of the government for 2013-14 is Rs 58,000 cr

Kalyan Jewellers raises Rs 1,200 cr from Warburg Pincus

Company is said to have diluted around 10-12% stake to the PE firm

Pulse prices move up on lower kharif output estimates

Lower kharif production estimates fuel the rise; fall in global output also likely to keep prices up

UP sugar crisis defuses as mills ready to go for cane crushing

Private mills owe farmers Rs 2,500 crore in arrears for the earlier crushing season

Back to Top